Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1177/03946320110241S212 | DOI Listing |
Nanoscale
January 2025
Chongqing Key Laboratory of Inorganic Functional Materials, College of Chemistry, Chongqing Normal University, Chongqing, 401331, PR China.
The development of environmentally friendly, high-efficiency, stable, earth-abundant and non-precious metal-based electrocatalysts with fast kinetics and low overpotential for oxygen evolution reaction (OER) and hydrogen evolution reaction (HER) is of exceeding significance but still challenging. Herein, a bifunctional electrode of unique hierarchical NiFe-LDH/Ni/NiCoS/NF (NiFe-LDH = nickel-iron layered double hydroxide and NF = nickel foam) electrocatalytic architecture, which is built up from NiFe-LDH nanosheets, Ni nanoparticles and NiCoS nanoneedles sequentially arrayed on a porous NF substrate, has been prepared by a facile hydrothermal and electrodeposition method. This electrocatalytic architecture is binder-free and its outer NiFe-LDH nanosheets can effectively prevent the oxidation of inner Ni nanoparticles and corrosion of NiCoS nanoneedles during water electrolysis.
View Article and Find Full Text PDFChem Sci
January 2025
Shenzhen Key Laboratory of New Information Display and Storage Materials, College of Materials Science and Engineering, Shenzhen University Shenzhen 518060 P. R. China
Developing highly efficient deep-blue multi-resonance thermal activated delayed fluorescence (MR-TADF) materials for ultra-high-definition organic light-emitting diodes (OLEDs) displays that meet the stringent BT.2020 standard remains a significant challenge. In this study, we present a strategy to achieve high-performance deep-blue MR-TADF emitters by integrating a large π-conjugated double-boron-embedded MR skeleton with strategically positioned peripheral steric hindrance groups.
View Article and Find Full Text PDFGlob Reg Health Technol Assess
January 2025
Omakase Consulting S.L., Barcelona - Spain.
Background: Activated phosphoinositide 3-kinase (PI3K) δ Syndrome (APDS) is an ultra-rare, potentially life-threatening disease that lacks approved treatments in Spain. This study aimed to apply Multi-Criteria Decision Analysis (MCDA) to assess the value of the first pharmacological treatment for APDS in Spain.
Methods: A multidisciplinary group of 8 experts evaluated the selective PI3Kδ inhibitor leniolisib against Standard of Care (SoC).
Neuroradiol J
January 2025
Department of Radiology and Radiological Science, Medical University of South Carolina, USA.
We describe a novel application of photon-counting detector CT (PCD-CT) in neurovascular imaging by harnessing the improved spatial resolution, attenuation of electronic noise, and reduction of metal artifacts. The presented case offers the unique challenge of high-quality imaging for the assessment of treated and untreated intracranial saccular aneurysms, in the setting of metal artifacts from embolization coils. Our goal was to explore optimized reconstruction parameters for ultra-high-resolution imaging (UHR) using a dedicated, sharp neurovascular kernel (Hv72) and the highest strength of quantum iterative reconstruction (QIR-4) for detailed characterization of the vasculature.
View Article and Find Full Text PDFCancer Imaging
January 2025
Melbourne Theranostic Innovation Centre, Level 8, 14-20 Blackwood St, North Melbourne, VIC, 3051, Australia.
True total-body and extended axial field-of-view (AFOV) PET/CT with 1m or more of body coverage are now commercially available and dramatically increase system sensitivity over conventional AFOV PET/CT. The Siemens Biograph Vision Quadra (Quadra), with an AFOV of 106cm, potentially allows use of significantly lower administered radiopharmaceuticals as well as reduced scan times. The aim of this study was to optimise acquisition protocols for routine clinical imaging with FDG on the Quadra the prioritisation of reduced activity given physical infrastructure constraints in our facility.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!